Understanding the EVOQUE System: A Breakthrough in Transcatheter Tricuspid Valve Replacement
For patients living with symptomatic severe tricuspid regurgitation (TR), the options for treatment have historically been limited. Even as medications can manage symptoms, they don’t address the underlying valve failure, which can lead to a decline in quality of life and high mortality rates. The introduction of the EVOQUE Tricuspid Valve Replacement System marks a significant shift in cardiac care as the world’s first transcatheter tricuspid valve replacement (TTVR) therapy.
- The EVOQUE system is designed to eliminate tricuspid regurgitation through a minimally invasive transcatheter approach.
- Clinical data from the TRISCEND II trial shows superior cardiovascular outcomes and improved quality of life compared to medical therapy alone.
- The system offers procedural efficiency with an average device time of approximately one hour.
- Recent 2-year data presented at ACC.26 demonstrates sustained near elimination of TR.
What is the EVOQUE System?
The EVOQUE system is a specialized medical device designed to replace a failing tricuspid valve without the need for open-heart surgery. It utilizes a transfemoral 28F outer diameter delivery system, which is engineered for maneuverability and is used across all available valve sizes.
To accommodate a broad range of patient anatomies, the system is available in multiple sizes. During the pivotal TRISCEND II trial, the valve was offered in four specific sizes: 44, 48, 52, and 56 mm. This flexibility allows clinicians to treat a diverse population of patients with varying tricuspid anatomy.
Clinical Evidence: The TRISCEND II Trial
The safety and effectiveness of the EVOQUE system were rigorously evaluated in the TRISCEND II trial. This prospective, multi-center, randomized controlled trial compared the employ of the EVOQUE system plus optimal medical therapy against optimal medical therapy alone in 400 patients with symptomatic severe TR.
Key Findings and Outcomes
- Superior Clinical Benefit: The trial demonstrated that orthotopic TTVR using the EVOQUE valve, combined with medical therapy, is superior to medical therapy alone in improving cardiovascular outcomes.
- Quality of Life: Improvements were primarily driven by a reduction in symptoms and enhanced measures of quality of life.
- Safety Profile: The trial reported no significant differences in mortality or heart failure (HF) hospitalizations between the TTVR group and the control group.
- Long-term Durability: Data presented at ACC.26 regarding 2-year outcomes showed a significant and sustained near elimination of tricuspid regurgitation among patients.
Who is a Candidate for EVOQUE TTVR?
TTVR is intended for patients who have severe functional or degenerative tricuspid regurgitation and continue to experience signs or symptoms despite optimal medical therapy (such as stable oral diuretic medications) or those who have previously been hospitalized for heart failure due to TR.
Patient Eligibility Criteria
To ensure safety and efficacy, the TRISCEND II trial established specific inclusion and exclusion criteria:
Inclusion Criteria
- Symptomatic severe TR despite optimal medical therapy.
- Anatomy suitable for the EVOQUE valve.
Exclusion Criteria
- Left ventricular ejection fraction (LVEF) less than 25%.
- Severe right ventricular (RV) dysfunction.
- Prior heart transplantation or previous tricuspid surgery/intervention.
- Estimated glomerular filtration rate (eGFR) ≤25 mL/min/1.73m².
- Pacemaker dependency without an alternative pacing option.
Comparing TR Management Options
| Approach | Mechanism | Primary Goal |
|---|---|---|
| Medical Therapy | Pharmacological management (e.g., diuretics) | Manage symptoms; does not treat the TR itself |
| EVOQUE TTVR | Transcatheter valve replacement | Eliminate TR and improve quality of life |
Frequently Asked Questions
How is the EVOQUE system delivered?
The system uses a transfemoral delivery method with a 28F outer diameter, designed for maneuverability and ease of use during the procedure.
How long does the procedure take?
According to clinical data, the average device time for the EVOQUE system is approximately one hour.
Does the EVOQUE system reduce mortality?
In the TRISCEND II trial, while the system showed superior improvement in symptoms and quality of life, there were no reported differences in mortality compared to medical therapy alone.
The Future of Tricuspid Valve Therapy
The emergence of the EVOQUE system represents a pivotal moment in cardiology, providing a viable alternative for patients who previously had few options beyond medical management. With 2-year data confirming sustained results, TTVR is establishing a new standard of care for the treatment of symptomatic severe tricuspid regurgitation.